New Company Showcase
FibromEd Limited
Many potential new therapeutics fail during
clinical trials because of safety and toxicity issues.
FibromEd was incorporated in 2011 by the
Edinburgh BioQuarter team and combines the assets and know-how from
the University of Edinburgh in generating high fidelity human
hepatocytes for research and safety and toxicity testing.
The FibromEd approach uses human pluripotent
stem cells as its model system. FibromEd is playing a central role
in the tools development space, with an initial focus, but not
limited to, the generation of predictive and reliable human liver
models.
The Company is developing a new stem-cell
derived hepatocyte system, HepatoinformTM, to address
the worldwide shortage of active primary human hepatocytes. The
system will have applications in human metabolite and toxicity
screening, with more sophisticated phase II products currently
under development. It will sell directly and partner with existing
companies and CRO’s with existing distribution chains.
It is looking for an ‘A’ round of investment
of up to £2 million and for potential business partners and to
build its business team.
View other
Showcase Videos
Videos produced in association with film company, Small
Majority.
Disclaimer:
None of the content in or by Edinburgh Science
Triangle constitutes investment advice or an invitation to
subscribe for securities within the meaning of the Financial
Services & Markets Act 2000 and derivative regulations (“the
Act”). Anyone who wishes to pursue any opportunity appearing
in these pages should consult an adviser who is authorised for the
purposes of the Act to ensure that its provisions are properly
complied with.
